Alector to Present at the Stifel 2020 Virtual Healthcare Conference
Alector, a clinical-stage biotechnology company focused on immuno-neurology, announced that Dr. Sabah Oney will speak at the Stifel 2020 Virtual Healthcare Conference on November 18, 2020, at 4:40 p.m. ET. The event will be accessible via a live webcast on Alector's investor website, with a replay available for 30 days post-event. Alector is developing innovative therapies targeting the immune system to address neurodegenerative diseases, including frontotemporal dementia and Alzheimer’s, emphasizing a novel approach to treating these conditions.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Sabah Oney, Ph.D., chief business officer of Alector, will participate in a fireside chat at the Stifel 2020 Virtual Healthcare Conference on Wednesday, November 18, 2020, at 4:40 p.m. ET.
A live webcast of the fireside chat will be available on the “Events & Presentations” page within the Investors section of the Alector website at http://investors.alector.com. A replay will be available on the Alector website for 30 days following the event.
About Alector
Alector is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. The Company is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable the rejuvenated immune cells to counteract emerging brain pathologies. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The Company’s immuno-neurology product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimer’s disease. This scientific approach is also the basis for the Company’s immuno-oncology programs. Alector is headquartered in South San Francisco, California. For additional information, please visit www.alector.com.
Contacts
Media:
Erica Jefferson
Vice President, Communications and Public Affairs
Alector, Inc.
301-928-4650
erica.jefferson@alector.com
1AB
Dan Budwick
973-271-6085
dan@1abmedia.com
or
Investors:
Alector, Inc.
ir@alector.com
FAQ
What event is Alector participating in on November 18, 2020?
Who from Alector will speak at the Stifel conference?
Where can I watch the Alector conference live stream?
How long will the Alector conference replay be available?
What is Alector's focus in biotechnology?
